LINGO1 and myeloid sarcoma: Several medications aimed at enhancing OPC differentiation have been tested in patients with MS, including clemastine (a first-generation antihistamine) [10], opicinumab (a human monoclonal antibody against LINGO-1) [51], and bexarotene (a clinically approved RXR agonist) [52].